News und Analysen
Lantheus and Progenics Agree to Amended Transaction Terms
Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative
NanoString Highlights Groundbreaking Spatial Genomics Research Using Expanding Portfolio of GeoMx High-Plex RNA Atlas Products at 2020 Advances in Genome Biology and Technology (AGBT) Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced ten scientific studies utilizing the GeoMx™ Digital
ICON Acquires MedPass International
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has
New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commends the recent international consensus statement published in the Journal of Affective Disorders for
Premier Inc. ProvideGx™ Program Partners with Pfizer Inc. to Provide Corvert® and Vincristine to Providers
Premier Inc. (NASDAQ: PINC), through its ProvideGx™ program, has partnered with Pfizer Inc. to supply Corvert® (ibutilide fumarate injection) and Vincristine Sulfate Injection, USP, to healthcare
Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System
DexCom, Inc. (NASDAQ: DXCM) and Insulet Corporation (NASDAQ: PODD), have announced a global commercialization agreement to combine current and future Dexcom continuous glucose monitoring systems
Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System
DexCom, Inc. (NASDAQ: DXCM) and Insulet Corporation (NASDAQ: PODD), have announced a global commercialization agreement to combine current and future Dexcom continuous glucose monitoring systems
Agilent Technologies Reports First Quarter Fiscal Year 2020 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.36 billion for the first quarter ended Jan. 31, 2020, up 5.7% year over year (and up 2.4% on a core(1) basis).
On a GAAP basis
Quidel to Present at Upcoming Conferences
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the
Lantheus Holdings to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of
Medicare ACOs in Premier Inc. Collaborative Outperform Peers in Shared Savings by 21 Percent
Medicare Accountable Care Organizations (ACOs) participating in the Premier Inc. (NASDAQ: PINC) Population Health Management Collaborative (PHMC) have outperformed their peers by 21 percent in
Lantheus Holdings to Host Fourth Quarter and Full Year 2019 Earnings Conference Call on February 25, 2020 at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Tuesday, February 25, 2020, to discuss its financial and operating
Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that it will
European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved VYNDAQEL® (tafamidis), a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary
European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved VYNDAQEL® (tafamidis), a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary
NanoString to Present at the 40th Annual Cowen Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced that the company’s management is scheduled to present at the 40th
Canopy Growth: Das war der Befreiungsschlag!
Wie ein zu Barrons gehörendes bedeutendes Online-Finanzportal berichtet, würden die Anleger billiges Marihuana bevorzugen. Canopy Growth (WKN: A140QA) sei dabei derjenige Branchenplayer, der im
Lysogene Reports its Cash Position as of 31 December 2019
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today
Canopy Growth: Was Aurora kann...
...kann Canopy Growth (WKN: A140QA) schon lange. Nein, Canopy kann es sogar viel besser. Der Cannabis-Marktführer meldet heute Quartalszahlen, die im Gegensatz zu den Horrorzahlen von Aurora
Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019.
Fourth Quarter 2019 Highlights:
-
Revenue grew 37% versus the
Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019.
Fourth Quarter 2019 Highlights:
-
Revenue grew 37% versus the
Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2019 financial results on Monday, February 24, 2020, after the close of the U.S. financial markets. Clovis’
Quidel Reports Fourth Quarter and Full Year 2019 Financial Results
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
SVB Leerink Global